Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
07 06 2022
Historique:
pubmed: 25 5 2022
medline: 10 6 2022
entrez: 24 5 2022
Statut: ppublish

Résumé

Impairment of visual acuity is a serious public health problem in older adults. The number of persons 60 years or older with impaired visual acuity (defined as best corrected visual acuity worse than 20/40 but better than 20/200) was estimated at 2.91 million in 2015, and the number who are blind (defined as best corrected visual acuity of 20/200 or worse) was estimated at 760 000. Impaired visual acuity is consistently associated with decreased quality of life in older persons, including reduced ability to perform activities of daily living, work, and drive safely, as well as increased risk of falls and other unintentional injuries. To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for impaired visual acuity in older adults. Asymptomatic adults 65 years or older who present in primary care without known impaired visual acuity and are not seeking care for vision problems. The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in asymptomatic older adults. The evidence is lacking, and the balance of benefits and harms cannot be determined. More research is needed. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement).

Identifiants

pubmed: 35608838
pii: 2792705
doi: 10.1001/jama.2022.7015
doi:

Types de publication

Journal Article Practice Guideline Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2123-2128

Commentaires et corrections

Type : CommentIn
Type : SummaryForPatientsIn

Auteurs

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

University of North Carolina at Chapel Hill.

Michael Cabana (M)

Albert Einstein College of Medicine, New York, New York.

David Chelmow (D)

Virginia Commonwealth University, Richmond.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

John W Epling (JW)

Virginia Tech Carilion School of Medicine, Roanoke.

Carlos Roberto Jaén (CR)

The University of Texas Health Science Center, San Antonio.

Alex H Krist (AH)

Fairfax Family Practice Residency, Fairfax, Virginia.
Virginia Commonwealth University, Richmond.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

John M Ruiz (JM)

University of Arizona, Tucson.

Melissa A Simon (MA)

Northwestern University, Chicago, Illinois.

James Stevermer (J)

University of Missouri, Columbia.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH